Brain-derived neurotrophic factor blood levels are decreased in schizophrenia patients and associate with rs6265 genotypes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Zakharyan R;Zakharyan R; Boyajyan A; Boyajyan A
  • Source:
    Clinical biochemistry [Clin Biochem] 2014 Aug; Vol. 47 (12), pp. 1052-5. Date of Electronic Publication: 2014 Apr 05.
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: United States NLM ID: 0133660 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2933 (Electronic) Linking ISSN: 00099120 NLM ISO Abbreviation: Clin Biochem Subsets: MEDLINE
    • Publication Information:
      Publication: Tarrytown, NY : Elsevier Science
      Original Publication: [Toronto] Canadian Society of Clinical Chemists.
    • Subject Terms:
      Brain-Derived Neurotrophic Factor/*blood ; Schizophrenia/*blood; Adult ; Female ; Genotype ; Humans ; Male ; Middle Aged ; Schizophrenia/genetics
    • Abstract:
      Objectives: A growing number of studies implicate brain-derived neurotrophic factor (BDNF), an important promoter of synaptic transmission and neural plasticity, in the pathogenesis of schizophrenia. However, the existing data are controversial, that may reflect population differences between studied groups.
      Design and Methods: In the present study we performed a comparative analysis of BDNF plasma levels and its relation with rs6265 (G196A; Val66Met) polymorphism of BDNF gene (BDNF) in schizophrenia-affected and healthy subjects (controls) of the Armenian population. To check the influence of antipsychotics on BDNF plasma levels both medicated and non-medicated patients were involved in this study. Patients with paranoid form of schizophrenia chronically treated with typical antipsychotics (n=103), age- and sex-matched controls (n=105), and 25 antipsychotic-naive first-episode schizophrenia patients were involved. The levels of BDNF in the blood plasma were measured with a solid-phase enzyme-linked immunosorbent assay.
      Results: Decreased plasma levels of BDNF in both medicated and non-medicated schizophrenia patients compared to controls were observed. No significant difference in BDNF levels between medicated and non-medicated patients was detected. It was also detected that, compared to individuals homozygous for the standard allele (G/G) of rs6265, carriers of the rs6265 minor allele (A/G+A/A), which is significantly more frequent in schizophrenia patients than in controls, had decreased BDNF levels.
      Conclusions: The data obtained suggested that the pathogenesis of schizophrenia is characterized by genetically predetermined decreased blood levels of BDNF. These results indicated that genetically determined alterations of neuroimmune modulators may be among the risk factors of schizophrenia and contribute to disease-specific pathologic changes in functional activity of both the neuronal synaptic plasticity and the immune system.
      (Copyright © 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Keywords: Brain-derived neurotrophic factor; Plasma levels; Schizophrenia; rs6265 Polymorphism
    • Accession Number:
      0 (Brain-Derived Neurotrophic Factor)
    • Publication Date:
      Date Created: 20140410 Date Completed: 20150413 Latest Revision: 20140812
    • Publication Date:
      20221213
    • Accession Number:
      10.1016/j.clinbiochem.2014.03.021
    • Accession Number:
      24713399